Department of Health and Human Services
Issuing Organization
Centers for Disease Control and Prevention (NCHSTP/CDC), at http://www.cdc.gov/nchstp/od/nchstp.html
Participating Organizations
Centers for Disease Control and Prevention (CDC), at http://www.cdc.gov
Components of Participating Organizations
National Center for HIV, STD and TB Prevention (NCHSTP/CDC), at http://www.cdc.gov/nchstp/od/nchstp.html
Title: HIV Prevention Intervention Research with HIV-positive Incarcerated Populations
The CDC policies, guidelines, terms, and conditions stated in this announcement may differ from those used by the NIH.
Authority: This program is authorized under the Public Health Service Act, Section 301(a), 42 U.S.C. 241(a), as amended, and Section 317(a), 42 U.S.C. 247b(a), as amended.
Announcement Type
New
Request For Applications (RFA) Number: RFA-PS-06-011
Catalog of Federal Domestic Assistance
Number(s)93.941 HIV Demonstration, Research, Public and Professional Education
Projects
Key Dates
Release Date: February 27, 2006
Letter of Intent Receipt Date: March 23, 2006
Application Receipt Date(s):
April 20,
2006
Peer Review Date:
06/2006
Council Review Date:
07/2006
Earliest Anticipated Start Date: September 1, 2006
Expiration Date: April
21, 2006
Due Date for E.O. 12372
Due no later than 60 days after the application
receipt date.
Additional Overview Content
Executive Summary
Table of Contents
Part I Overview
Information
Part II Full Text of Announcement
Section I. Funding Opportunity
Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost Sharing or Matching
3.Other - Special Eligibility Criteria
Section IV. Application and Submission
Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Receipt and Review
and Anticipated Start Dates
1. Letter
of Intent
B. Sending an Application
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review
Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Sharing Research Data
D. Sharing Research Resources
3. Anticipated Announcement and Award
Dates
Section VI. Award Administration
Information
1. Award Notices
2. Administrative and National Policy
Requirements
A. Cooperative Agreement
Terms and Conditions of Award
1. Principal
Investigator Rights and Responsibilities
2. CDC Responsibilities
3. Collaborative
Responsibilities
3. Reporting
Section
VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
4. General Questions Contact(s)
Part II - Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The CDC and NCHSTP are committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010" and to measuring program performance as stipulated by the Government Performance and Review Act (GPRA). This RFA addresses “Healthy People 2010” priority area(s) of HIV and is in alignment with NCHSTP performance goal(s) to develop and implement effective HIV prevention interventions. For more information, see www.health.gov/healthypeople and www.whitehouse.gov/omb/mgmt-gpra/.
The purpose of this research funding announcement is to evaluate interventions that reduce risk behaviors of persons with HIV and increase their access to medical care, HIV prevention, and other supportive services after release from prison, e.g., substance abuse and PCRS. The interventions must be initiated with HIV-positive inmates prior to their release from prison and must link them to services in the community following release. The majority of the intervention must be provided during incarceration, however, intervention activities may continue in the community post-release.
In the United States, approximately 1.4 million people are incarcerated in Federal and State prisons. The prevalence of HIV among incarcerated persons is about two percent nationally, but varies substantially among different geographic areas. Ninety percent of prisoners are released. Thus, the health and well-being of prisoners is an issue that can affect the health of their partners, their families, and their communities.
Prior research has demonstrated the ability of individual and group-level interventions to increase HIV knowledge among incarcerated persons, and reduce the sexual risks of HIV-negative inmates post-release. Research has also found that interventions delivered to HIV-positive inmates during incarceration are feasible, but limited evidence exists regarding the efficacy of interventions for HIV-positive persons who are incarcerated and released from prison. Additional research is needed to rigorously evaluate the effectiveness of interventions that seek to reduce risk behaviors of HIV-positive inmates, and increase their access and adherence to medical treatment, and prevention services after release to the community.
This research will support three awards. Each awardee will identify and work collaboratively with local researchers, correctional facilities, health departments, and CDC to conduct intervention studies for HIV-positive inmates returning to the community.
A single common intervention is not expected across sites. Each site will identify and propose an intervention for HIV-positive inmates that can consist of one or more activities addressing the prevention of HIV transmission to others, access to medical care, and adherence to medical care, antiretroviral treatment, substance abuse treatment, PCRS, and other available prevention services. All interventions must include promotion of abstinence, faithful monogamy, and correct, consistent condom use (ABC). The proposed intervention must be feasible for implementation at the collaborating correctional institutions. The proposed intervention must be primarily conducted in prison, however, post-release intervention activities can be a component of the intervention. Regardless of the nature of the proposed intervention, each applicant must demonstrate a capacity to refer and link HIV-positive persons to appropriate medical treatment, and prevention services post-release.
Each awardee will be responsible for evaluating the positive and negative effects of the proposed intervention (and its cost) using a comparison group with a small sample of subjects (50 – 100 per arm) to provide preliminary evidence of effectiveness. The intervention and comparison groups could be from one or more than one prison. Persons in the comparison group should be provided the current standard of care for persons with HIV in that facility. Applicants should not stop or limit existing prevention activities in the participating facilities to qualify for this research program.
To allow for comparisons of effectiveness among the interventions, awardees will collaborate in the development of a limited number of common data elements (e.g., demographic characteristics and risk behaviors), and will collaboratively develop common data collection and management procedures. These standards will be determined in post-award grantee meetings.
See Section
VIII, Other Information - Required Federal Citations, for policies related
to this announcement.
Section II. Award Information
1. Mechanism(s) of Support
This funding opportunity will use the UR 6 award mechanism.
This funding opportunity uses the just-in-time budget
concepts. It also uses the non-modular budget format described in the PHS
398 application instructions (see http://grants.nih.gov/grants/funding/phs398/phs398.html).
A detailed categorical budget for the "Initial Budget Period" and
the "Entire Proposed Period of Support" is to be submitted with
the application.
The CDC UR 6 is a cooperative
agreement award mechanism. In the cooperative agreement mechanism, the Principal
Investigator retains the primary responsibility and dominant role for planning,
directing, and executing the proposed project, with CDC staff being substantially
involved as a partner with the Principal Investigator, as described under
the Section VI. 2. Administrative Requirements, "Cooperative Agreement
Terms and Conditions of Award".
2. Funds Available
The participating CIO, NCHSTP, intends to commit approximately $900,000 including both direct and indirect costs in FY 2006 to fund three awards. The average award amount will be approximately $300,000 including both direct and indirect costs for the first 12-month budget period. An applicant may request a project period of up to two years. An applicant may request up to $320,000 for the first 12-month budget period. The approximate total project period funded amount is $600,000 per awardee. The anticipated start date for new awards is September 1, 2006.
All estimated funding amounts are subject to availability of funds.
If you request a funding amount higher than the ceiling of the award range, your application will be considered non-responsive, and will not be entered into the review process. You will be notified that your application did not meet the submission requirements.
Facilities and administrative costs requested by consortium participants are not included in the direct cost limitation; see NOT-OD-05-004.
Section III. Eligibility Information
1. Eligible Applicants
1.A. Eligible Institutions
You may submit (an) application(s) if your organization has any of the following characteristics:
A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If you are applying as a bona fide agent of a state or local government, you must provide a letter from the state or local government as documentation of your status. Place this documentation behind the first page of your application form.
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for CDC programs.
Additional Principal Investigator qualifications are as follows:
2. Cost Sharing or Matching
Cost sharing, matching, or cost participation is not required for this program.
The most current Grants Policy Statement can be found at: http://grants.nih.gov/grants/policy/policy.htm
3. Other-Special Eligibility Criteria
Applications may be considered non-responsive under the following conditions:
If your application is incomplete or non-responsive to the special requirements listed in this section, it will not be entered into the review process.
Note: Title 2 of the United States Code Section 1611 states that an organization described in Section 501(c)(4) of the Internal Revenue Code that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, or loan.
Section IV. Application and Submission Information
1. Address to Request Application
Information
The PHS 398 application instructions are available
at http://grants.nih.gov/grants/funding/phs398/phs398.html
in an interactive format. Applicants must use the currently approved version
of the PHS 398. For further assistance contact GrantsInfo, Telephone (301)
435-0714, Email: GrantsInfo@nih.gov.
CDC Telecommunications for the
hearing impaired: TTY 770-488-2783.
2. Content and Form of Application Submission
Applications must be prepared using the most current PHS 398 research grant
application instructions and forms. Applications must have a Dun & Bradstreet
(D&B) Data Universal Numbering System number as the universal identifier
when applying for Federal grants or cooperative agreements. The D&B number
can be obtained by calling (866) 705-5711 or through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of the face page of the PHS
398 form.
The title and number of this funding opportunity must be typed on line 2 of
the face page of the application form and the YES box must be checked.
3. Submission Dates and Times
All requested information must be received in the CDC Procurement and Grants Office by 4:00 p.m. Eastern Time on April 10, 2006. If you submit your application by the United States Postal Service or commercial delivery service, you must ensure that the carrier will be able to guarantee delivery by the closing date and time. If CDC receives your submission after closing due to: (1) carrier error, when the carrier accepted the package with a guarantee for delivery by the closing date and time, or (2) significant weather delays or natural disasters, you will be given the opportunity to submit documentation of the carrier’s guarantee. If the documentation verifies a carrier problem, CDC will consider the submission as having been received by the deadline.
This announcement is the definitive guide on LOI and application content, submission address, and deadline. It supersedes information provided in the application instructions. If your application does not meet the deadline described in Section IV.3.A, it will not be eligible for review, and will be discarded. You will be notified that you did not meet the submission requirements.
Otherwise, CDC will not notify
you upon receipt of your submission. If you have a question about the receipt
of your application, first contact your courier. If you still have a question,
contact the PGO-TIMS staff at: 770-488-2700. Before calling, please wait
two to three days after the submission deadline. This will allow time for
submissions to be processed and logged.
3.A. Receipt, Review and Anticipated
Start Dates
Letter of Intent Receipt Date: March 23, 2006
Application Receipt Date(s): April 20, 2006
Peer Review Date: 06/2006
Council Review Date: 07/2006
Earliest Anticipated Start Date: September 1, 2006
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter
of intent that includes the following information:
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NCHSTP staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed in Section IV.3.A
The letter of intent should be sent to:
Amy L. Sandul, Scientific Program
Administrator
Extramural Research Program Office
National Center for HIV, STD and TB Prevention
Centers for Disease Control and Prevention
Mailstop E - 07
1600 Clifton Road, NE
Atlanta, GA 30333
Telephone: (404) 639-6485
FAX: (404) 639-8600
Email: ASandul@cdc.gov
3.B. Sending an Application
Applications follow the PHS 398 application instructions for content and formatting of your applications. If the instructions in this announcement differ in any way from the PHS 398 instructions, follow the instructions in this announcement.
Applications must be prepared using the research grant applications found in the PHS 398 instructions for preparing a research grant application. Submit a signed, typewritten original of the application and all appendices, including the checklist, and one signed photocopy in one package to:
Technical Information Management Section – RFA PS06-011
CDC, Procurements and Grants Office
2920 Brandywine Road
Atlanta, GA 30341
At the time of submission, three additional copies of the application, including the appendix material, must be sent to:
Michael Vance, Grants Technical Assistant
Extramural Research Program Office
National Center for HIV, STD and TB Prevention
Centers for Disease Control and Prevention
Mailstop E - 07
1600 Clifton Road, NE
Atlanta, GA 30333
Telephone: (404) 639 - 8006
FAX: (404) 639 - 8600
Email: MVance@cdc.gov
3.C. Application Processing
Applications must be received on or before the
application receipt date(s) described above (Section IV.3.A.). If an application
is received after that date, it will be returned to the applicant without
review. Upon receipt, applications will be evaluated for completeness and
responsiveness by NCHSTP and PGO. Incomplete and non-responsive applications will not be reviewed.
4. Intergovernmental Review
Your application is subject to Intergovernmental Review of Federal Programs, as governed by Executive Order (EO) 12372. This order sets up a system for state and local governmental review of proposed federal assistance applications. You should contact your state single point of contact (SPOC) as early as possible to alert the SPOC to prospective applications, and to receive instructions on your state’s process. Click on the following link to get the current SPOC list: http://www.whitehouse.gov/omb/grants/spoc.html
5. Funding Restrictions
All CDC awards are subject to the terms and conditions,
cost principles, and other considerations described in the PHS Grants Policy
Statement.
Restrictions, which must be taken into account while writing your budget, are as follows:
6. Other Submission Requirements
Awardees must agree to the "Cooperative Agreement
Terms and Conditions of Award" in Section VI. "Award Administration
Information".
If you are requesting indirect costs in your budget, you must include a copy of your indirect cost rate agreement. If your indirect cost rate is a provisional rate, the agreement should be less than 12 months of age.
Your research plan should address activities to be conducted over the entire project period.
Plan for Sharing Research Data
The precise content of the data-sharing plan will vary, depending on the data being collected and how the investigator is planning to share the data. Applicants may wish to describe briefly the expected schedule for data sharing, the format of the final dataset, the documentation to be provided, whether or not any analytic tools also will be provided, whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement (including the criteria for deciding who can receive the data and whether or not any conditions will be placed on their use), and the mode of data sharing (e.g., under their own auspices by mailing a disk or posting data on their institutional or personal website, through a data archive or enclave). References to data sharing may also be appropriate in other sections of the application.
All applicants must include a plan for sharing research
data in their application. The data sharing policy is available at http://www.cdc.gov/od/pgo/funding/ARs.htm
under Additional Requirements 25 Release and Sharing of Data. All investigators
responding to this funding opportunity should include a description of how
final research data will be shared, or explain why data sharing is not possible.
The reasonableness of the data sharing plan or the rationale for not sharing
research data will be assessed by the reviewers. However, reviewers will not
factor the proposed data sharing plan into the determination of scientific
merit or the priority score.
Sharing Research Resources
Not Applicable
Section V. Application Review Information
1. Criteria
Only the review criteria described
below will be considered in the review process.
The following will be considered in making funding decisions:
2. Review and Selection Process
Applications that are complete and responsive to
the RFA will be evaluated for scientific and technical merit by an appropriate
peer review group convened by OPHR in accordance with the review criteria
stated below.
As part of the initial merit review, all applications will:
The goals of CDC-supported research are to advance the understanding of health promotion and prevention of disease, injury, and disability, and enhance preparedness. In the written comments, reviewers will be asked to evaluate the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals.
Significance:
Does this study address an important problem? If the aims of the application
are achieved, how will scientific knowledge or clinical practice be advanced?
What will be the effect of these studies on the concepts, methods, technologies,
treatments, services, or preventative interventions that drive this field?
Are the proposed study activities likely to have a significant impact on the
field of HIV prevention for the study population?
Approach: Are the conceptual or clinical framework, design,
methods, and analyses adequately developed, well integrated, well reasoned,
and appropriate to the aims of the project? Does the applicant acknowledge
potential problem areas and consider alternative tactics? Does the applicant
propose partnering with the Department of Corrections on all aspects of conducting
the study? Is the proposed intervention supported by the state or local health
department as indicated by a letter of support? Does the applicant propose
an intervention that is likely to have a significant and positive impact on
preventing HIV transmission? Is the intervention likely to increase access
to medical care, adherence to treatment services (e.g., antiretroviral and
substance abuse), and prevention services (PCRS) for HIV-positive persons
post-release? Does the applicant propose an intervention that is reasonably
sustainable beyond the funding period? Does the applicant propose a mechanism
to routinely identify HIV-positive inmates who are scheduled for release from
prison? Does the applicant propose a recruitment strategy that is directed
toward all known HIV-positive inmates or a representative sample of this population?
Has the applicant summarized prior research findings that support the approach
of the proposed intervention? Does the applicant propose a rigorous and scientifically
sound plan to evaluate the effects of the intervention using an appropriate
comparison group? Does the proposed evaluation allow for the evaluation of
positive and unanticipated negative effects of the intervention? Does the
applicant propose to recruit an adequate number of eligible participants to
detect differences between the two study groups? Does the applicant propose
an adequate plan to determine the effectiveness of the intervention 3 months
after release from prison or, if post-release intervention activities are
conducted, completion of post-release intervention contact? Does the evaluation to determine
the success of the intervention contain outcome measures that include, but
are not limited to, abstinence from sexual activity and drug use, faithful
monogamy, consistent and correct condom use, and use of appropriate services
in the community? Does the applicant present a high quality plan for data
management and analysis? Does the applicant propose an adequate plan to collect
information about the cost of conducting the intervention? Does the proposed
intervention address the needs of HIV positive inmates and is it culturally
appropriate?
Innovation: Is the project original and innovative? For example:
Does the project challenge existing paradigms or clinical practice; address
an innovative hypothesis or critical barrier to progress in the field? Does
the project develop or employ novel concepts, approaches, methodologies, tools,
or technologies for this area? Does the project employ a novel intervention
approach that is likely to reduce HIV transmission and increase access to
medical care, adherence to care and treatment services, and use of Prevention
services?
Investigators: Are the investigators appropriately trained
and well suited to carry out this work? Is the work proposed appropriate to
the experience level of the principal investigator and other researchers?
Does the investigative team bring complementary and integrated expertise to
the project (if applicable)? Does the investigative team have adequate experience
conducting research with incarcerated populations or similar groups of HIV
positive persons? Does the investigative team have prior experience collaborating
with Departments of Corrections? Does the investigative team have an adequate
appreciation of the issues relevant for prisoners while they are incarcerated
and following their release? Does the investigative team have adequate experience
developing and implementing prevention programs? Does key staff have sufficient
time devoted to this project to ensure success? If individual interviews
will be conducted, does the investigative team have experience conducting
interviews utilizing audio-computer-assisted-self-interview (A-CASI) methods
for data collection? Does the investigator have experience in conducting
interventions that include promotion of abstinence, faithful monogamy and
correct, consistent condom use (ABC)?
Environment: Does the scientific environment in which the
work will be done contribute to the probability of success? Do the proposed
studies benefit from unique features of the scientific environment, or subject
populations, or employ useful collaborative arrangements? Is there evidence
of institutional support? Will the planned prison facilities provide access
to adequate numbers of the target population? Does the applicant demonstrate
a strong partnership with a Department of Corrections as evidenced by the
inclusion of a memorandum of agreement indicating permission for intervention
implementation and evaluation activities to be conducted, as planned, in participating
prison facilities?
2.A. Additional Review Criteria:
In addition to the above criteria, the following items will continue to be
considered in the determination of scientific merit and the priority score:
Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed (see the Research Plan, Section E on Human Subjects in the PHS Form 398). http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Additional CDC Requirements under AR-1 Human Subjects Requirements can be found on http://www.cdc.gov/od/pgo/funding/ARs.htm.
Inclusion of Women and
Minorities in Research:
Does the application adequately address the CDC Policy requirements regarding
the inclusion of women, ethnic, and racial groups in the proposed research?
This includes: (1) The proposed plan for the inclusion of both sexes and racial
and ethnic minority populations for appropriate representation; (2) The proposed
justification when representation is limited or absent; (3) A statement as
to whether the design of the study is adequate to measure differences when
warranted; and (4) A statement as to whether the plans for recruitment and
outreach for study participants include the process of establishing partnerships
with community(ies) and recognition of mutual benefits.
2.B. Additional Review Considerations
Budget: The
reasonableness of the proposed budget and the requested period of support
in relation to the proposed research. The priority score should not be affected
by the evaluation of the budget.
2.C. Sharing Research Data
Data Sharing Plan:
The reasonableness of the data sharing plan or the rationale for not sharing
research data will be assessed by the reviewers. However, reviewers will not
factor the proposed data sharing plan into the determination of scientific
merit or the priority score. The presence of a data sharing plan will be part
of the terms and conditions of the award. The funding organization will be
responsible for monitoring the data sharing policy.
2.D. Sharing Research Resources
Program staff will be responsible for the administrative
review of the plan for sharing research resources.
The adequacy of the resources
sharing plan will be considered by Program staff of the funding organization
when making recommendations about funding applications. Program staff may
negotiate modifications of the data and resource sharing plans with the awardee
before recommending funding of an application. The final version of the data
and resource sharing plans negotiated by both will become a condition of the
award of the grant. The effectiveness of the resource sharing will be evaluated
as part of the administrative review of each non-competing Grant Progress
Report (PHS 2590 http://www.cdc.gov/od/pgo/forminfo.htm).
See Section VI.3. Reporting .
3. Anticipated Announcement and Award Dates
It is anticipated that awards will be announced by September 1, 2006.
Section VI. Award Administration
Information
1. Award Notices
After the peer review of the application is completed,
the Principal Investigator will also receive a written critique called a Summary
Statement.
Those applicants under consideration for funding will
be contacted by CDC for additional information.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the Grants Management Officer (GMO) is the authorizing document. This document will be mailed and/or emailed to the recipient fiscal officer identified in the application.
Selection of the application for award is not an authorization to begin performance. Any cost incurred before receipt of the NoA is at the recipient’s risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See also Section IV.5. Funding Restrictions.
2. Administrative and National Policy Requirements
The Code of Federal Regulations
45 CFR Part 74 and Part 92 have details about policy requirements. For more
information on the Code of Federal Regulations, see the National Archives
and Records Administration at the following Internet address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
Additional requirements can be found in Section VIII. Other Information of
this document or on the CDC website at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm.
These will be incorporated into the NoA by reference.
2.A. Cooperative Agreement Terms and Conditions of Award
The following special terms of
award are in addition to, and not in lieu of, otherwise applicable OMB administrative
guidelines, HHS grant administration regulations at 45 CFR Parts 74 and 92
(Part 92 is applicable when State and local Governments are eligible to apply),
and other HHS, PHS, and CDC grant administration policies.
The administrative and funding instrument used for this program will be the
cooperative agreement, UR 6, an "assistance" mechanism (rather than
an "acquisition" mechanism), in which substantial CDC programmatic
involvement with the awardees is anticipated during the performance of the
activities. Under the cooperative agreement, the CDC purpose is to support
and stimulate the recipients' activities by involvement in and otherwise working
jointly with the award recipients in a partnership role; it is not to assume
direction, prime responsibility, or a dominant role in the activities. Consistent
with this concept, the dominant role and prime responsibility resides with
the awardees for the project as a whole, although specific tasks and activities
may be shared among the awardees and the CDC as defined above.
2.A.1. Principal Investigator Rights and Responsibilities
The Principal Investigator will have the primary responsibility for:
Awardees will retain custody
of and have primary rights to the data and software developed under these
awards, subject to Government rights of access consistent with current HHS,
PHS, and CDC policies.
2.A.2. CDC Responsibilities
A CDC Project Scientist will have substantial programmatic involvement that
is above and beyond the normal stewardship role in awards, as described below.
Additionally, an agency program official or CIO program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.
2.A.3. Collaborative Responsibilities
A Steering committee will be
established consisting of a CDC Project Scientist and Principal Investigators.
Each full member will have one vote. Awardee members of the Steering Committee
will be required to accept and implement policies approved by the Steering
Committee.
3. Reporting
You must provide CDC with an original, plus two
hard copies of the following reports:
These reports must be forward by U.S. Postal Service or Express Delivery to the Grants Management Specialist listed in the “Agency Contacts” section of this announcement.
Although the financial plans of the CIO(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.
We encourage your inquiries concerning
this funding opportunity and welcome the opportunity to answer questions from
potential applicants. Inquiries may fall into three areas: scientific/research,
peer review, and financial or grants management issues:
1. Scientific/Research Contacts:
Amy L. Sandul, Scientific Program Administrator
Extramural Research Program Office
National Center for HIV, STD and TB Prevention
Centers for Disease Control and Prevention
Mailstop E - 07
1600 Clifton Road, NE
Atlanta, GA 30333
Telephone: (404) 639-6485
FAX: (404) 639 - 8600
Email: ASandul@cdc.gov
2. Peer Review Contacts:
M. Chris Langub, PhD
Office of Public Health Research
Centers for Disease Control and Prevention
Mailstop D - 72
1600 Clifton Road, NE
Atlanta, GA 30333
Telephone: (404) 639-4640
FAX: (404) 639-4903
Email: MLangub@cdc.gov
3. Financial or Grants Management
Contacts:
Angie Tuttle, Grants Management Specialist
Procurement and Grants Office
Centers for Disease Control and Prevention
Mailstop E – 15
2900 Brandywine Road
Atlanta, GA 30341
Telephone: (404) 639-8305
FAX: (404) 639-8095
Email: ATuttle@cdc.gov
4. General Questions Contacts:
Technical Information Management Section
CDC Procurement and Grants Office
2920 Brandywine Road
Atlanta, GA 30341
Telephone: 770-488-2700
Email: PGOTIM@cdc.gov
Section VIII. Other Information
Required Federal Citations
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving
human subjects must be evaluated with reference to the risks to the subjects,
the adequacy of protection against these risks, the potential benefits of
the research to the subjects and others, and the importance of the knowledge
gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Additional CDC Requirements under AR-1 Human Subjects Requirements can be
found on http://www.cdc.gov/od/pgo/funding/ARs.htm.
Research activities supported under this announcement must comply with the
requirements of 45 CFR part 46, subpart C (Additional Protections Pertaining
to Biomedical and Behavioral Research Involving Prisoners as Subjects). All
institutions engaged in this research must submit certification to the Office
for Human Research Protections (OHRP) that their Institutional Review Board
has approved the research under 45 CFR part 46 subpart C (Additional Protections
Pertaining to Biomedical and Behavioral Research Involving Prisoners as Subjects)
and request concurrence that the research supported by DHHS may involve prisoners
as subjects. Interaction with prisoners cannot begin until notification from
OHRP is received.
Requirements for Inclusion of Women and Racial and Ethnic
Minorities in Research
It is the policy of the Centers for Disease Control and
Prevention (CDC) and the Agency for Toxic Substances and Disease Registry
(ATSDR) to ensure that individuals of both sexes and the various racial and
ethnic groups will be included in CDC/ATSDR-supported research projects involving
human subjects, whenever feasible and appropriate. Racial and ethnic groups
are those defined in OMB Directive No. 15 and include American Indian or Alaska
Native, Asian, Black or African American, Hispanic or Latino, Native Hawaiian
or Other Pacific Islander. Applicants shall ensure that women, racial and
ethnic minority populations are appropriately represented in applications
for research involving human subjects. Where clear and compelling rationale
exist that inclusion is inappropriate or not feasible, this situation must
be explained as part of the application. This policy does not apply to research
studies when the investigator cannot control the race, ethnicity, and/or sex
of subjects. Further guidance to this policy is contained in the Federal Register,
Vol. 60, No. 179, pages 47947-47951, and dated Friday, September 15, 1995.
HIV/AIDS Confidentiality Provisions
Recipients must have confidentiality and security provisions
to protect data collected through HIV/AIDS surveillance, including copies
of local data release policies; employee training in confidentiality provisions;
State laws, rules, or regulations pertaining to the protection or release
of surveillance information; and physical security of hard copies and electronic
files containing confidential surveillance information.
Describe laws, rules, regulations, or health department policies that require or permit the release of patient-identifying information collected under the HIV/AIDS surveillance system to entities outside the public health department; describe also the measures the health department has taken to ensure that persons reported to the surveillance system are protected from further or unlawful disclosure.
Some projects may require Institutional Review Board (IRB) approval or a certificate of confidentiality.
HIV Program Review Panel Requirements
Compliance with Content of AIDS-Related Written Materials,
Pictorials, Audiovisuals, Questionnaires, Survey Instruments, and Educational
Sessions (June 1992) is required.
To meet the requirements for a program review panel, you are encouraged to use an existing program review panel, such as the one created by the State health department's HIV/AIDS prevention program. If you form your own program review panel, at least one member must be an employee (or a designated representative) of a State or local health department. List the names of the review panel members on the Assurance of Compliance form, CDC 0.1113. Submit the program review panel's report that all materials have been approved.
If the proposed project involves hosting a conference, submit the program review panel's report stating that all materials, including the proposed conference agenda, have been approved. Submit a copy of the proposed agenda with the application.
Before funds are used to develop educational materials, determine whether suitable materials already exist in the CDC National AIDS Clearinghouse.
Patient Care
Ensure that all STD or HIV infected patients enrolled
in the proposed project will be linked to an appropriate local care system
that can address their specific needs, such as medical care, counseling, social
services, and therapy.
Executive Order 12372 Review
Applications are subject to Intergovernmental Review of
Federal Programs, as governed by Executive Order (E.O.) 12372. The order sets
up a system for State and local governmental review of proposed Federal assistance
applications. Applicants should contact their State single point of contact
(SPOC) as early as possible to alert the SPOC to prospective applications
and to receive instructions on the State process. For proposed projects serving
more than one State, the applicant is advised to contact the SPOC for each
State affected.
Click on the following link to get the current SPOC list
http://www.whitehouse.gov/omb/grants/spoc.html
Indian tribes must request tribal government review of their applications.
SPOCs or tribal governments that have recommendations about an application submitted to CDC should send them, in a document bearing the program announcement number, no more than 60 days after the application deadline date, to:
Angie Tuttle, Grants Management Specialist
Procurement and Grants Office
Announcement Number RFA PS06-011
Centers for Disease Control and Prevention (CDC)
2920 Brandywine Road
Atlanta, Georgia 30341-4146
CDC does not guarantee to accept or justify its non-acceptance of recommendations that are received more than 60 days after the application deadline.
Public Health System Reporting Requirements
This program is subject to the Public Health System Reporting
Requirements. Under these requirements, all community-based non-governmental
organizations submitting health services applications must prepare and submit
the items identified below to the head of the appropriate State and/or local
health agency(s) in the program area(s) that may be impacted by the proposed
project no later than the application deadline date of the Federal application.
The appropriate State and/or local health agency is determined by the applicant.
The following information must be provided:
A. A copy of the face page of the application (SF 424).
B. A summary of the project that should be titled "Public Health System Impact Statement" (PHSIS), not exceed one page, and include the following:
1. A description of the population to be served.
2. A summary of the services to be provided.
3. A description of the coordination plans with the appropriate state and/or local health agencies.
If the State and/or local health official should desire a copy of the entire application, it may be obtained from the State Single Point of Contact (SPOC) or directly from the applicant.
Paperwork Reduction Act Requirements
Under the Paperwork Reduction Act, projects that involve
the collection of information from 10 or more individuals and funded by a
grant or a cooperative agreement will be subject to review and approval by
the Office of Management and Budget (OMB).
Smoke-Free Workplace Requirements
CDC strongly encourages all recipients to provide a smoke-free
workplace and to promote abstinence from all tobacco products. Public Law
103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities
that receive Federal funds in which education, library, day care, health care,
or early childhood development services are provided to children.
In addition no part of CDC appropriated funds, shall be used, other than for normal and recognized executive-legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support or defeat legislation pending before the Congress or any State or local legislature, except in presentation to the Congress or any State or local legislature itself. No part of the appropriated funds shall be used to pay the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence legislation or appropriations pending before the Congress or any State or local legislature.
Any activity designed to influence action in regard to a particular piece of pending legislation would be considered "lobbying." That is lobbying for or against pending legislation, as well as indirect or "grass roots" lobbying efforts by award recipients that are directed at inducing members of the public to contact their elected representatives at the Federal or State levels to urge support of, or opposition to, pending legislative proposals is prohibited. As a matter of policy, CDC extends the prohibitions to lobbying with respect to local legislation and local legislative bodies.
The provisions are not intended to prohibit all interaction with the legislative branch, or to prohibit educational efforts pertaining to public health. Clearly there are circumstances when it is advisable and permissible to provide information to the legislative branch in order to foster implementation of prevention strategies to promote public health. However, it would not be permissible to influence, directly or indirectly, a specific piece of pending legislation
It remains permissible to use CDC funds to engage in activity to enhance prevention; collect and analyze data; publish and disseminate results of research and surveillance data; implement prevention strategies; conduct community outreach services; provide leadership and training, and foster safe and healthful environments.
Recipients of CDC grants and cooperative agreements need to be careful to prevent CDC funds from being used to influence or promote pending legislation. With respect to conferences, public events, publications, and "grassroots" activities that relate to specific legislation, recipients of CDC funds should give close attention to isolating and separating the appropriate use of CDC funds from non-CDC funds. CDC also cautions recipients of CDC funds to be careful not to give the appearance that CDC funds are being used to carry out activities in a manner that is prohibited under Federal law.
Accounting System Requirements
The services of a certified public accountant licensed
by the State Board of Accountancy or the equivalent must be retained throughout
the project as a part of the recipient's staff or as a consultant to the recipient's
accounting personnel. These services may include the design, implementation,
and maintenance of an accounting system that will record receipts and expenditures
of Federal funds in accordance with accounting principles, Federal regulations,
and terms of the cooperative agreement or grant.
Capability Assessment
It may be necessary to conduct an on-site evaluation
of some applicant organization's financial management capabilities prior to
or immediately following the award of the grant or cooperative agreement.
Independent audit statements from a Certified Public Accountant (CPA) for
the preceding two fiscal years may also be required.
Small, Minority, And Women-owned Business
It is a national policy to place a fair share of purchases
with small, minority and women-owned business firms. The Department of Health
and Human Services is strongly committed to the objective of this policy and
encourages all recipients of its grants and cooperative agreements to take
affirmative steps to ensure such fairness. In particular, recipients should:
1. Place small, minority, women-owned business firms on bidders mailing lists.
2. Solicit these firms whenever they are potential sources of supplies, equipment, construction, or services.
3. Where feasible, divide total requirements into smaller needs, and set delivery schedules that will encourage participation by these firms.
4. Use the assistance of the Minority Business Development Agency of the Department of Commerce, the Office of Small and Disadvantaged Business Utilization, DHHS, and similar state and local offices.
Research Integrity
The signature of the institution official on the face page
of the application submitted under this Funding Opportunity Announcement is
certifying compliance with the Department of Health and Human Services (DHHS)
regulations in Title 42 Part 93, Subparts A-E, entitled PUBLIC HEALTH SERVICE
POLICIES ON RESEARCH MISCONDUCT.
The regulation places requirements on institutions receiving or applying for funds under the PHS Act that are monitored by the DHHS Office of Research Integrity (http://ori.hhs.gov./policies/statutes.shtml).
For example:
Section 93.301 Institutional assurances.(a) General policy. An institution with PHS supported biomedical or behavioral research, research training or activities related to that research or research training must provide PHS with an assurance of compliance with this part, satisfactory to the Secretary. PHS funding components may authorize [[Page 28389]] funds for biomedical and behavioral research, research training, or activities related to that research or research training only to institutions that have approved assurances and required renewals on file with ORI. (b) Institutional Assurance. The responsible institutional official must assure on behalf of the institution that the institution-- (1) Has written policies and procedures in compliance with this part for inquiring into and investigating allegations of research misconduct; and (2) Complies with its own policies and procedures and the requirements of this part.
Compliance with Executive Order 13279
Faith-based organization are eligible to receive federal
financial assistance, and their applications are evaluated in the same manner
and using the same criteria as those for non-faith-based organizations in
accordance with Executive Order 13279, Equal Protection of the Laws for Faith-Based
and Community Organizations. All applicants should, however, be aware of
restrictions on the use of direct financial assistance from the Department
of Health and Human Services (DHHS) for inherently religious activities. Under
the provisions of Title 45, Parts 74, 87, 92 and 96, organizations that receive
direct financial assistance from DHHS under any DHHS program may not engage
in inherently religious activities, such as worship, religious instruction,
or proselytization as a part of the programs or services funded with direct
financial assistance from DHHS. If an organization engages in such activities,
it must offer them separately, in time or location, from the programs or services
funded with direct DHHS assistance, and participation must be voluntary for
the beneficiaries of the programs or services funded with such assistance.
A religious organization that participates in the DHHS funded programs or
services will retain its independence from Federal, State, and local governments,
and may continue to carry out its mission, including the definition, practice,
and expression of its religious beliefs, provided that it does not use direct
financial assistance from DHHS to support inherently religious activities
such as those activities described above. A faith-based organization may,
however, use space in its facilities to provide programs or services funded
with financial assistance from DHHS without removing religious art, icons,
scriptures, or other religious symbols. In addition, a religious organization
that receives financial assistance from DHHS retains its authority over its
internal governance, and it may retain religious terms in its organization=s
name, select its board members on a religious basis, and include religious
references in its organization=s mission statements and other governing documents
in accordance with all program requirements, statutes, and other applicable
requirements governing the conduct of DHHS funded activities. For further
guidance on the use of DHHS direct financial assistance see Title 45, Code
of Federal Regulations, Part 87, Equal Treatment for Faith-Based Organizations,
and visit the internet site:
http://www.whitehouse.gov/government/fbci/
Health Insurance Portability and Accountability Act
Requirements
Recipients of this grant award should note that pursuant
to the Standards for Privacy of Individually Identifiable Health Information
promulgated under the Health Insurance Portability and Accountability Act
(HIPAA) (45 CFR Parts 160 and 164) covered entities may disclose protected
health information to public health authorities authorized by law to collect
or receive such information for the purpose of preventing or controlling disease,
injury, or disability, including, but not limited to, the reporting of disease,
injury, vital events such as birth or death, and the conduct of public health
surveillance, public health investigations, and public health interventions.
The definition of a public health authority includes a person or entity acting
under a grant of authority from or contract with such public agency. CDC
considers this project a public health activity consistent with the Standards
for Privacy of Individually Identifiable Health Information and CDC will provide
successful recipients a specific grant of public health authority for the
purposes of this project.
Release and Sharing of Data
The Data Release Plan is the Grantee's assurance that
the dissemination of any and all data collected under the CDC data sharing
agreement will be released as follows:
a. In a timely manner.
b. Completely, and as accurately as possible.
c. To facilitate the broader community.
d. Developed in accordance with CDC policy on Releasing and Sharing Data.
April 16, 2003, http://www.cdc.gov/od/foia/policies/sharing.htm, and in full compliance with the 1996 Health Insurance Portability and Accountability Act (HIPPA), (where applicable), The Office of Management and Budget Circular A110, (2000) revised 2003, www.whitehouse.gov/omb/query.html?col=omb&qt=Releasing+and+Sharing+of+Data and Freedom of Information Act (FOIA) www.4.law.cornell.edu/uscode/5/5/552/html.
Applications must include a copy of the applicant's Data Release Plan. Applicants should provide CDC with appropriate documentation on the reliability of the data. Applications submitted without the required Plan may be ineligible for award. Award will be made when reviewing officials have approved an acceptable Plan. The successful applicant and the Program Manager will determine the documentation format. CDC recommends data is released in the form closest to micro data and one that will preserve confidentiality.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |